{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/background-information/causes/","result":{"pageContext":{"chapter":{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field 8497d64f-4248-4d91-88f1-ee3240849abd --><h2>What causes it?</h2><!-- end field 8497d64f-4248-4d91-88f1-ee3240849abd -->","summary":"","htmlStringContent":"<!-- begin item 58adb351-d2fb-40fe-be37-2cfadfdc5b64 --><!-- begin field a4db80a9-bcb0-45b2-92d6-b4709344f250 --><ul><li><strong>There is no known single cause for atopic eczema.</strong> It is a complex condition involving genetic, immunologic, and environmental factors, leading to a dysfunctional skin barrier and immune system dysregulation.<ul><li>Recent evidence suggests that mutations in the filaggrin gene is a likely cause for almost 50% of cases of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nutten, 2015</a>] (the filaggrin gene is essential for the conversion of keratinocytes to the protein/lipid squames that make up the outermost barrier layer of the skin [the stratum corneum]). A defect in filaggrin causes skin barrier dysfunction.</li><li>The primary function of the skin barrier is to restrict water loss and to prevent entry of irritants, allergens, and skin pathogens. The resulting skin barrier dysfunction is thought to [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nutten, 2015</a>]:<ul><li>Cause water loss from the skin, leading to dryness and itching.</li><li>Make the skin susceptible to allergens, leading to hyperreactivity and induction of immunoglobulin E (IgE) autoantibodies. </li><li>Predispose the skin to colonization or infection by microbes, such as <em>Staphylococcus aureus</em>, also leading to an inflammatory response and further damage of the skin barrier. </li></ul></li><li>Another theory is that T helper cell dysregulation (a predominance of Th2 cells rather than Th1) results in production of IgE and mast cell hyperactivity, leading to the development of pruritus, inflammation, and other clinical features of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</li><li>About 70% of people with atopic eczema have a positive family history of atopic disease (atopic eczema, asthma, and/or hay fever) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>].<ul><li>Atopic eczema presents in about 80% of children where both parents are affected, and in 60% if only one parent is affected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Uehara and Kimura, 1993</a>].</li><li>Twin studies have shown concordance rates of 77–85% in monozygotic (identical) twins and 15–21% in dizygotic (non-identical) twins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>], and have estimated prevalence in siblings at 22–24% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>].</li></ul></li></ul></li><li><strong>Several factors have been proposed as triggers for atopic eczema,</strong> mainly as a result of epidemiological studies in which exposure to one or more of these factors has been shown to be associated with increased incidence of atopic eczema and/or exacerbation of established atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>].<ul><li>Possible trigger factors include soap and detergent, animal dander, house-dust mites, extreme temperatures, rough clothing, pollen, certain foods, and stress.</li><li>While most triggers lead to reactions confined to the skin, allergic triggers can induce both skin and systemic responses. These responses are largely mediated via IgE and T cell responses causing immediate (type 1) allergic reactions and/or delayed (late-phase or type 4) allergic reactions.<ul><li>Immediate reactions can lead to erythema and itching, urticaria (hives), and/or angioedema, resulting in an acute flare of atopic eczema. Systemic effects involving the gastrointestinal tract (GIT, oral itching, vomiting, diarrhoea, and/or abdominal pain), the respiratory tract (rhinitis, wheeze, cough, and difficulty breathing), or the cardiovascular system (drop in blood pressure and/or collapse) may also occur. The involvement of breathing difficulties or a drop in blood pressure constitutes an anaphylactic reaction.</li><li>Delayed reactions cause itching and flares of atopic eczema and may be accompanied by GIT symptoms (vomiting and/or diarrhoea).</li></ul></li><li>For more information on trigger factors, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/diagnosis/identifying-trigger-factors/\">Identifying trigger factors</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nutten, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Stein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BAD, 2017</a>]</p><!-- end field a4db80a9-bcb0-45b2-92d6-b4709344f250 --><!-- end item 58adb351-d2fb-40fe-be37-2cfadfdc5b64 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}